Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol Effect on Anemia in CKD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* age \> 18~* written informed consent~* CKD stage 3-5 (eGFR \<60 ml/min/1,73 m2)~* PTH 30-300 pg/ml~* Hb \<10 g/dl \>3 consecutive months~* Ferritin \> 100 ng/ml~* transferrin saturation (TSAT) 20-40%~* mean corpuscular volume (MCV) 85-95%~* for patients treated with Ace-inhibitors or angiotensin receptor blockers, dose stable \>3 months~* for patients treated with erythropoiesis-stimulating agents (ESA), dose stable \>3 months~Exclusion criteria:~* anemia due to non renal cause~* presence of malignancies, inflammatory or infectious disease \>3 months~* pregnancy~* bleeding \>6 months~* C-reactive protein (CRP) \>1 mg/dl~* poorly controlled hypertension (PAS \> 170 mmHG and PAD \>100 mmHg)~* severe malnutrition~* hypercalcemia (\>10,5 mg/dl)~* hyperphosphatemia (\>5,5 mg/dl)~* surgical interventions \>3 months~* acute myocardial infarction, unstable angina, stroke or transitory ischemic attack, deep venous or pulmonary thromboembolism, congestive heart failure \>3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Patients receiving treatment for secondary hyperparathyroidism with calcitriol. The calcitriol dosage schedule provided for an initial dose of 0.5 mch every other day and titration was performed on the basis of the serum levels of intact PTH (iPTH) (target 150-300 pg/mL), Ca, P and Ca x P product as suggested by the US National Kidney Foundation Dialysis outcomes Quality Initiative (NKF-DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
- Paricalcitol (Type: EXPERIMENTAL): Patients treated by Paricalcitol for hyperparathyroidism. The paricalcitol initial dose was 1 mcg/die, and titration was performed on the basis of the serum levels of iPTH, Ca, P and Ca x P product as suggested by the NKF-DOQI and KDIGO guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).